Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial.
This trial aims to assess the cardiovascular safety of survodutide in people with obesity and cardiovascular risk factors, with a target enrollment of nearly 5,000 participants.
Where it sits
this study against the rest of the survodutide (bi 456906) corpusSummary and findings
This study outlines the design of the SYNCHRONIZE-CVOT, a phase 3 trial assessing the cardiovascular safety of survodutide, a dual glucagon and GLP-1 receptor agonist, in adults with obesity and cardiovascular risk factors. The primary endpoint is the time to first occurrence of a composite of major adverse cardiovascular events. The trial is currently enrolling with a target of 4,935 participants.
Abstract
Dual agonism of glucagon and glucagon-like peptide-1 (GLP-1) receptors may be more effective than GLP-1 receptor agonism alone in reducing body weight, but the cardiovascular (CV) effects are unknown. The authors describe the rationale and design of SYNCHRONIZE-CVOT, a phase 3, randomized, double-blind, parallel-group, event-driven, CV safety study of survodutide, a dual glucagon and GLP-1 receptor agonist, administered subcutaneously once weekly compared with placebo in adults with a body mass index ≥27 kg/m<sup>2</sup> and established CV disease or chronic kidney disease, and/or at least 2 weight-related complications or risk factors for CV disease. The primary endpoint of SYNCHRONIZE-CVOT is time to first occurrence of the composite adjudicated endpoint of 5-point major adverse CV events. This global CV outcomes trial is currently enrolling, with a target recruitment of 4,935 participants. SYNCHRONIZE-CVOT is the first trial that will determine the CV safety and efficacy of survodutide in people with obesity and increased CV risk. (A Study to Test the Effect of Survodutide [BI 456906] on Cardiovascular Safety in People With Overweight or Obesity [SYNCHRONIZE-CVOT]; NCT06077864).
Background
The SYNCHRONIZE trial addresses the clinical question of how Survodutide affects cardiovascular outcomes in individuals with obesity. Previous studies have indicated that obesity is a significant risk factor for cardiovascular diseases, but the specific effects of Survodutide on these outcomes have not been thoroughly investigated. This study is essential as it aims to fill this gap in knowledge.
Methods
The study design is a cardiovascular outcomes trial, but specific details regarding the population, sample size, dosing regimen, duration, and outcome measures are not provided in the abstract. It is crucial to understand these factors to evaluate the robustness of the findings.
Results
Not reported in abstract.
Interpretation
Without specific results reported, it is challenging to compare the findings to existing literature or assess the clinical significance of Survodutide's effects. The lack of detailed results raises concerns about the ability to draw meaningful conclusions from this trial. Practitioners should remain cautious until more comprehensive data is available.
Key findings
- Not reported in abstract.
Limitations
- Not reported in abstract.